
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is a promising medical device company with a positive outlook for revenue and gross margin growth this year, as well as potential partnerships, product launches, and market expansion. While its profitability outlook has decreased, the company is expected to see future growth and profitability. However, there are potential risks and challenges that could impact the company's performance and stock value. A buy rating and price target of $18 have been given based on projected revenue growth and profitability in the upcoming years.
Bears say
SI-BONE is currently experiencing strong revenue growth, however their dependence on a single anatomical location and potential headwinds in reimbursement and coverage could impact future growth and profitability. With a relatively high valuation and increasing competition in the market, there are risks to consider when investing in SI-BONE. However, their focus on a specialized niche and differentiated products could also lead to sustained growth and above-average profitability in the future. More research and monitoring of the company's market penetration and competitive landscape may be needed to fully assess their potential.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares